Neoadjuvant BOT/BAL - (NEOASIS)

July 17, 2026: Agenus, Inc. (NASDAQ: AGEN) announced that three abstracts from investigator-sponsored studies of botensilimab plus balstilimab (BOT+BAL) were accepted for poster presentation at the ESMO Congress 2026 (Oct 23–27, 2026; Madrid). The posters cover: (1) NEOASIS—updated neoadjuvant BOT+BAL data in mismatch repair-deficient (dMMR) colorectal cancer (poster 837P; Colon cancer session; Oct 25, 2026, 12:00–12:45 CET); (2) real-world data from a Spanish expanded access program of BOT+BAL in advanced sarcoma (poster 3771P; Sarcoma session; Oct 26, 2026, 12:00–12:45 CET); and (3) real-world multicenter AGEO study data of BOT+BAL in refractory pMMR/MSS metastatic colorectal cancer (ePoster 905eP; Colon cancer session; date/time not stated). The release notes NEOASIS is biologically distinct from the MSS/pMMR population planned for the ROBBIN study and supports the rationale for evaluating BOT+BAL earlier (pre-surgery) in colon cancer. No efficacy or safety results are provided in the text.